Oxford's Covid-19 vaccine is being brought to Bangladesh by Beximco Pharmaceuticals Limited. The Serum Institute of India is cooperating in this.

Beximco Pharmaceuticals Limited (BPL), one of the largest pharmaceutical and pharmaceutical companies in Bangladesh, and Serum Institute of India Private Limited (SII) Covid-1, the world's largest vaccine manufacturer, said in a press release on Friday (August 26th). BPL will invest in SII.

This investment will be considered as an advance. When the vaccine is approved by the regulatory authority, SII will include Bangladesh among the first countries to receive a certain amount of vaccine on a priority basis.

The amount of BPL's investment and the amount of SII's priority vaccine supply for Bangladesh will depend on SII's production capacity and the company's previous commitments with other countries.

BPL will also take steps to ensure the needs of the Bangladesh government. The government will be offered to provide vaccines as per the demand for priority supply at an agreed price between the Government of Bangladesh and SII. BPL will ensure the supply of vaccines to the private market in Bangladesh.

The Oxford / AstraZeneca vaccine (AZD122) is an adenovirus vector-based vaccine. The third phase of the vaccine is currently being tested on a large scale in Brazil, the United States, the United Kingdom and India.

SII owner and CEO Adar C. Punawala and BPL principal Shayan F. Rahman said in a joint statement, "We are delighted to be able to bring together two top pharma companies in India and Bangladesh to deliver this highly promising vaccine to the doorsteps of those most in need." . The agreement will be a milestone as a reflection of the deep goodwill of cooperation between the two countries.

"As representatives of the two nations, together we can go a long way in resolving the health crisis caused by the Kovid-19 epidemic."